S49.F Supernus Pharmaceuticals Inc

Healthcare Pharmaceuticals Frankfurt Exchange
37.20 EUR
Close of Nov 13, 2026
23.00 47.80
Market cap
EUR 2.17B
P/E
-
P/B
5.55x
ROE
-5.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is S49.F undervalued?

Graham number

The Graham number of Supernus Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Supernus Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Supernus Pharmaceuticals Inc yet.

Supernus Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia in patients with Parkinson's disease (PD) receiving levodopa/carbidopa; Oxtellar XR, an extended-release oxcarbazepine product indicated for mono…

Full company profile